Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6359027 | 0.92 | ALB (0.50) | APEX1SIRT2SMN1; SMN2LMNAKMT2A | |
| SCHEMBL6357891 | 0.92 | APEX1 (0.51) | APEX1SIRT2SMN1; SMN2LMNAPOLB | |
| SCHEMBL6352393 | 0.86 | APEX1 (0.52) | APEX1SIRT2SMN1; SMN2LMNAPOLB | |
| SCHEMBL6352847 | 0.86 | SIRT2 (0.52) | APEX1SIRT2SMN1; SMN2LMNAPOLB | |
| SCHEMBL6349541 | 0.85 | SIRT2 (0.51) | APEX1SIRT2SMN1; SMN2LMNAPOLB | |
| SCHEMBL6352026 | 0.85 | SIRT2 (0.51) | APEX1SIRT2SMN1; SMN2LMNAPOLB | |
| SCHEMBL6352680 | 0.83 | SIRT2 (0.51) | APEX1SIRT2SMN1; SMN2LMNAPOLB | |
| SCHEMBL6350364 | 0.83 | ALB (0.51) | APEX1SIRT2SMN1; SMN2LMNAKMT2A | |
| SCHEMBL6352584 | 0.82 | APEX1 (0.48) | APEX1SIRT2SMN1; SMN2LMNAPOLB | |
| SCHEMBL6834272 | 0.81 | ALB (0.36) | SIRT2KMT2AMEN1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | PHARMACIA & UPJOHN COMPANY | 2005-05-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | CLPP, SPOUT1, SAMHD1 | APEX1 502/4885SIRT2 3380/4885SMN1; SMN2 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.